Evoke Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 09:01 am EDT
Share
Evoke Pharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 1.87 million compared to USD 2.23 million a year ago. Basic loss per share from continuing operations was USD 0.56 compared to USD 0.71 a year ago. Diluted loss per share from continuing operations was USD 0.56 compared to USD 0.71 a year ago.
For the six months, net loss was USD 4.11 million compared to USD 4.41 million a year ago. Basic loss per share from continuing operations was USD 1.23 compared to USD 1.5 a year ago. Diluted loss per share from continuing operations was USD 1.23 compared to USD 1.5 a year ago.
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.